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Abstract 
Background: To reduce opioid dependence and HIV transmission, Kyrgyzstan has introduced methadone main-
tenance therapy and needle/syringe programs into prisons. Illicit injection of diphenhydramine, an antihistamine 
branded as  Dimedrol®, has been anecdotally reported as a potential challenge to harm reduction efforts in prisons 
but has not been studied systematically.
Methods: We conducted qualitative interviews in Kyrgyz or Russian with prisoners (n = 49), former prisoners (n = 19), 
and stakeholders (n = 18), including prison administrators and prisoner advocates near Bishkek, Kyrgyzstan from 
October 2016 to September 2018. Interviews explored social–contextual factors influencing methadone utilization in 
prisons. Transcripts were coded by five researchers using content analysis. Dimedrol injection emerged as an impor-
tant topic, prompting a dedicated analysis.
Results: After drinking methadone, some people in prison inject crushed Dimedrol tablets, a non-prescription anti-
histamine that is banned but obtainable in prison, to achieve a state of euphoria. From the perspectives of the study 
participants, Dimedrol injection was associated with devastating physical and mental health consequences, including 
psychosis and skin infections. Moreover, the visible wounds of Dimedrol injecting contributed to the perception of 
methadone as a harmful drug and supporting preference for heroin over methadone.
Conclusion: Dimedrol injecting is a potentially serious threat to harm reduction and HIV prevention efforts in Kyr-
gyzstan and elsewhere in the Eastern European and Central Asian region and requires further investigation.
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Background
[He] also died last year. I got his passport done for 
him. He has a mother and two brothers who sent 
money through me. I asked him, “What keeps you 
here?” I said to him, “Come on, I’ll take you to detox 
and you’ll spend ten days there and you’ll have a 
ticket, and I’ll take you straight to [a rehabilita-
tion center]…What keeps you here is Dimedrol only, 
nothing else. You’ve exchanged your relatives for 
Dimedrol!” He didn’t go and he ended up dying in 
a manhole. He shot up in the groin. Everything rot-
ted there. And we called the police officers. They took 
him out of the manhole already semi-decomposed. 
[Marina]
HIV incidence is declining globally, with many coun-
tries poised to achieve UNAIDS goals of zero new HIV 
infections by 2030 [1]. Yet, HIV incidence is increasing 
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in Eastern Europe and Central Asia (EECA) where 
drug injection is the primary driver of HIV transmis-
sion within the community. In the EECA region, HIV 
prevalence among people who inject drugs (PWID) is 
25–30%, compared to 0.8% HIV prevalence in the gen-
eral adult population [2]. Criminalization of drug use in 
EECA countries has concentrated people with HIV and 
substance use disorders (SUDs) into jails and prisons. 
Kyrgyzstan (Kyrgyz Republic) is an EECA country of six 
million people with high HIV prevalence (11.3%) among 
prisoners and detainees [3], most of whom (95%) are 
male [4] and one-third of whom are PWID [5, 6]. From 
2000 to 2018, Kyrgyzstan’s prison population declined 
by half, from 20,000 to approximately 10,000 detainees; 
however, seizures of illicit drugs and substance use within 
prisons increased during that same period. In 2012, two 
percent of all drug-related crime nationwide occurred in 
prisons [7], evidencing the need for a coordinated and 
comprehensive response to prevent, treat, and mitigate 
the harmful consequences of substance use within Kyr-
gyz prisons.
To address ongoing substance use and high HIV 
prevalence within its prisons, Kyrgyzstan implemented 
a comprehensive package of harm reduction and HIV 
prevention services in prisons as recommended by the 
United Nations Offices on Drugs and Crime (UNODC) 
and AIDS (UNAIDS), and the World Health Organiza-
tion (WHO) [8]. In 2001, Kyrgyzstan introduced nee-
dle syringe programs (NSP) into prisons, followed by 
a pilot methadone maintenance program (MMT) in 
2008. Despite availability of MMT and NSP in most of 
Kyrgyzstan’s 28 prisons, which together provide phar-
macological treatment with methadone to more than 
400 individual patients [9], utilization of MMT remains 
suboptimal and many people continue to use and inject 
drugs within prison [6]. NSP, which could reduce harmful 
consequences of drug injection, is not routinely offered 
to prisoners receiving MMT because they are assumed 
to be abstinent from heroin. Major barriers to MMT 
and NSP include stigma among prisoners and staff [10], 
restricted access, and a competing heroin market con-
trolled by the informal prison leadership, as we have 
described elsewhere [6].
Illicit injection of diphenhydramine in prison has been 
noted in government reports since 2006, but has not 
been assessed as a specific threat to individual patient 
health or MMT service expansion [11, 12]. Diphenhy-
dramine is an H1 antihistamine branded as  Dimedrol® 
in Kyrgyzstan. Though it has an opioid-sparing effect, 
Dimedrol readily crosses the blood–brain barrier into the 
central nervous system, resulting in predominantly seda-
tive and antiemetic effects [13]. As a class, antihistamines 
may theoretically have a synergistic effect with opioids 
because they inhibit opioid metabolism [14]. Antihista-
mines’ affinity for the dopamine receptor and potential 
to increase dopamine release, at least in vitro, may lead 
PWID to use it to “potentiate euphoria” with opioids or 
opioid agonists [15]. The combination of opioids with 
antihistamines has been a recurrent global trend, often 
noted in settings where MMT or heroin availability is 
scarce. For example, combined opioids and antihista-
mines were commonly known as a “lytic cocktail” in 
1950s France, “Blue Velvet” in the US in the 1960s, and 
“T’s and Blues” in the US in the 1980s [16]. Illicit anti-
histamine use has more recently been reported among 
patients receiving MMT in San Francisco [17] and among 
US patients receiving methadone for chronic pain [18]. 
The gray literature includes reports of Dimedrol injecting 
throughout the EECA among people in the community 
with opioid use disorders, including in Tajikistan [19], 
Russia [20], and Uzbekistan [21].
Dimedrol injecting is potentially detrimental to harm 
reduction and HIV prevention efforts, particularly in 
Kyrgyz prisons where HIV prevalence is high and metha-
done remains unpopular despite its availability for over 
a decade. We have previously described how the low 
uptake of methadone in Kyrgyz prisons is related to how 
other drugs are used in this context [22]. Despite its per-
sistent global popularity, antihistamine injecting has 
never been specifically addressed in terms of HIV pre-
vention, harm reduction, or public health. In this quali-
tative analysis, we describe Dimedrol injecting practices 
in Kyrgyz prisons and explore its health consequences, 
including as a possible influence upon prisoners’ accept-
ance and utilization of MMT.
Methods
Study setting
This study was conducted near Bishkek, Kyrgyzstan from 
October 2016 to September 2018. In Kyrgyz prisons, 
MMT is provided by the prison administration and deliv-
ered by trained medical staff to persons meeting DSM-IV 
criteria for opioid use disorder (OUD). In recognition of 
the availability of heroin in prison, NSP is also offered by 
the prison administration and available to any prisoner 
who requests sterile equipment for injecting. Within 
Kyrgyz prisons, an informal caste system is organized 
around prison labor and narcotic distribution. Those 
at the highest level of the prison hierarchy are informal 
prison leaders who dictate codes of conduct. Caste is 
assigned by compliance with these codes of conduct and 
organized around contribution of labor to the [obshchak], 
or prisoners’ common fund. Participation in the pris-
oner economy is rewarded with distribution of [razgon], 
or material rewards including heroin, which is trafficked 
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and controlled by informal prison leadership as described 
elsewhere [23].
The parent project was designed to longitudinally and 
qualitatively assess barriers to MMT uptake during and 
after incarceration and evaluate the ways in which the 
prison risk environment influenced perceptions and use 
of methadone. Findings on HIV risk [24] suggest that 
most PWID incarcerated in Kyrgyzstan continue to inject 
in prison [6], prisoners are organized into rigid hierar-
chies that perpetuate inequalities in access to HIV pre-
vention resources [23], and social factors shape patient 
engagement with methadone [22], especially after prison 
release and during the transition to communities [25] and 
among women [26]. Here, we explore the harmful health 
effects of Dimedrol injecting in prisons and implications 
for harm reduction programs.
Participant recruitment
Participants were recruited from Kyrgyzstan’s largest 
male prison, which houses more than 1000 men, and 
Kyrgyzstan’s only female prison, which houses approxi-
mately 280 women. Studies with nationally representative 
cohorts indicate higher prevalence of HIV among male 
prisoners (11.3%) compared to female prisoners (2.5%) 
[5], and male prisoners reporting higher rates of sub-
stance use within prison [6]. Eligible participants were 
18 years of age or older, within 6–12 months of scheduled 
prison release, reported having injected opioids in the 
12-months prior to incarceration, and planned to return 
to the Bishkek region on release. We used purposive 
sampling to recruit people from the soon-to-be released 
prison population who were diverse with respect to age, 
incarceration history, HIV status, and prior experiences 
with methadone [5] (Fig. 1: Group 1). We also recruited 
participants from a concurrent NIDA-funded imple-
mentation study of motivational interviewing for MMT 
initiation and retention through the post-release tran-
sitional period (Fig.  1: Group 2). Group 2 participants 
were only recruited for the qualitative study after they 
had completed the baseline motivational interview visit 
and declared their preferences for methadone; the same 
eligibility criteria were applied as to Group 1. To elicit 
accounts of within-prison substance use in an environ-
ment free from the constraints of the prison (i.e., time 
restrictions, pressures of informal prisoner subculture, 
etc.), we recruited additional participants from com-
munity organizations in Bishkek who reported lifetime 
history of incarceration in Kyrgyzstan (Fig. 1: Group 3). 
Additionally, we recruited stakeholders for interviews, 
including: (1) prison staff employed by the State Peniten-
tiary Service; (2) staff from non-governmental organiza-
tions who serve as advocates for returning prisoners; and 
(3) formerly incarcerated individuals who were identified 
as leaders within prisoner subculture (Fig. 1).
Study procedures
All participants completed informed consent procedures 
and a face-to-face, voice-recorded in-depth interview 
in Kyrgyz or Russian with a trained interviewer. Inter-
views were conducted in private rooms within each of 
the prison facilities and lasted ~ 30–60  min. Prison staff 
were never present during interviews. Interviews focused 
on social, interpersonal, and environmental factors that 
influence drug-related HIV-risk behaviors and participa-
tion in methadone treatment within prison and during 
community reentry. A topic guide covered the following 
Fig. 1 Study sampling overview
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central issues: social support, within-prison drug use, 
knowledge about and attitudes toward drug treatment, 
and interactions with other prisoners and prison staff. 
Interviews with prison staff sought to understand the 
prisoner social hierarchy (caste system) and economy, 
MMT, NSP, within-prison drug use, and perceptions of 
“us” (e.g., prisoners) versus “them” (e.g., prison staff or 
administration). Interviews were open-ended, and the 
topic guide was modified to incorporate emerging themes 
of interest, including Dimedrol. Because this study was 
designed as a longitudinal qualitative assessment, we 
conducted one interview per participant in prison prior 
to release and aimed to conduct one follow-up interview 
per participant in the community following release, using 
a similar (post-release) interview guide, which focused 
additionally on substance use in the community (Fig. 1).
Analysis
Voice-recorded interviews were transcribed verbatim 
and translated into English using a HIPAA-compliant 
service. Interview transcripts were also analyzed in Rus-
sian because several study team members (LA, JR, AK) 
are native Russian speakers, allowing for interpretation 
of the participant data in its original form. All identifying 
information was removed before transcripts were trans-
ferred for analysis. All transcripts were uploaded into 
Dedoose qualitative analytic software. Using an induc-
tive approach, five researchers independently coded the 
interviews using a shared codebook. Initial codes were 
informed by concepts of the risk environment frame-
work, including form of environmental influence and level 
of effect [27]. The codebook was then adapted as part of 
an iterative process to allow for “open coding” of par-
ticipant narratives. For the present analysis, all excerpts 
from the parent code “Dimedrol” were examined, includ-
ing: meanings of, descriptions of people who use, addic-
tion, intoxication from, attitudes toward people who use, 
prevalence of use, procedures of using, reasons for using, 
side effects from, relationship to methadone, polysub-
stance use with methadone, and polysubstance use with 
heroin. Excerpts were grouped around key themes based 
on study team consensus and discussion and illustrative 
quotes were selected for each. Participants are identified 
by pseudonyms as per sociology discipline convention 
and consistent with pseudonyms used in prior analyses 
from the parent study [28].
Results
Participant characteristics are shown in Table  1. 
Although qualitative data were drawn from interviews 
with nearly 20 women in prison, representative excerpts 
from only one woman are included here because Dime-
drol use was less common in the women’s prison where 
few women prisoners are prescribed methadone. People 
using MMT in prison were said to frequently combine 
methadone with Dimedrol to achieve a euphoria that was 
not possible with methadone alone. The major motiva-
tion for Dimedrol use was the belief that it increased the 
activity of methadone and strengthened its effects:
Dimedrol gives a push, they inject it to increase the 
effect of methadone, to get high. [Bashir]
I think it is stronger, more potent that heroin. Metha-
done and Dimedrol, in my opinion, are more potent. 
[Yryskul’]
Some participants suggested that Dimedrol use origi-
nated in the community where people injected low doses 
of Dimedrol to reduce nausea after heroin injection or 
injected Dimedrol in higher doses to strengthen the 
effects of low purity heroin:
It depends on the body of each and the heroin. Gen-
erally, you don’t find good heroin outside. In my 
days, a gram of heroin cost 1000 rubles. You take 
this gram, but only one tenth of it is heroin and nine 
tenths are sugar. We were shooting up sugar, and not 
heroin, and by adding [Dimedrol] tablets, it added 
strength. [Tursun]
Whereas Dimedrol was sometimes combined with her-
oin in the community, in prison, Dimedrol was only ever 
identified as being combined with methadone.
Health consequences of Dimedrol use: “They are walking 
around like zombies”
Participants frequently and vividly described Dimedrol 
injection as resulting in a range of negative mental and 
physical health effects. People who combined methadone 
and Dimedrol were described as becoming progressively 
withdrawn, forgetful, and confused:
Well, they would not answer your questions, some-
times they would talk nonsense and gibberish. 
Their eyes are crazy. I believe I heard someone say 
they would start going through garbage, or even put 
their hands in the toilet bowls. In a nutshell, people 
become just awful. [Turat]
I have no idea what they put in Dimedrol… but it 
makes you stall, unresponsive, it is hard to explain. 
It has stronger highs than heroin. [Yryskul’]
In addition to these altered behaviors, Dimedrol use was 
associated with skin and soft tissue infections, including 
abscesses and chronic wounds:
For so many years I had veins, when I started shoot-
ing up Dimedrol, in a matter of six months, all my 
veins were gone, in the groin and in my armpits. All 
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the things this Dimedrol has done, I almost lost my 
arm. [Sasha]
Participants described Dimedrol as short-acting and 
leading to tolerance, which required users to inject it in 
larger quantities and more frequently:
Before methadone, you shoot up five tablets. You 
drink methadone some 20  min later, it’s absorbed 
and you crush ten tablets of Dimedrol and you 
shoot up ten tablets, and it’s euphoria. An hour later 
another ten tablets. You do 50 tablets a day, can you 
imagine? [Sasha]
In addition to causing pain and disability, Dimedrol injec-
tion was described as visibly altering a person’s physical 
appearance and behaviors in ways that marked them as 
members of a hopelessly self-destructive caste scorned by 
medical staff and other prisoners:
Well those who take Dimedrol, it’s obvious. They 
shoot up, then they get abscesses. They’re always 
walking around in bandages. You can pick out such 
a person straight away. [Nikolay]
All of them are rotting, and such a smell, they really 
care little about this, how they smell and how they 
look. [Marina]
A guy here has already had his finger cut off. Now 
the second time his leg was cut off. The third time, 
I said, let them cut his head off and be done with it. 
[Tair]
Their behavior becomes different, yes. When they’re 
taking methadone, the person behaves exactly like 
you and me. But when it’s drugs [Dimedrol], if she’s 
taking something on top [of the methadone], this 
means that her behavior changes radically, as it is 
with drug addicts. [Oksana]
Although people who inject Dimedrol in prisons theo-
retically have access to the NSP, there are severe social 
sanctions against disclosing Dimedrol use, described fur-
ther below. As a result, most people who inject heroin in 
prison do so with sterile injecting equipment, whereas 
people who inject Dimedrol may have limited access 
to NSP and frequently share injecting equipment, with 
potential risk for transmission of blood-borne infections 
including HIV. Participants were divided about whether 
prisoners receiving MMT could access sterile syringes for 
injecting Dimedrol. Some participants felt that prisoners 
who used Dimedrol could access sterile syringes under 
the pretext of using needles to self-administer other 
medications.
Table 1 Table of attributes
PWID person who injects drugs, MMT methadone maintenance therapy, NA not applicable, M male, F female, NGO non-governmental organization
a The lowest caste of prisoners
b Literally, “the decent ones.” Second to highest and largest caste in the prisoner hierarchy
c Refers to prisoners who work for the formal prison administration
d The second to lowest caste in the prisoner hierarchy
e One of the higher castes in the prisoner hierarchy, a leader within prison subculture





Bashir Obizhennyia M 26–30 1–5 0 3 5–6
Yryskul’ NA F 31–35 6–10 0 2 1–2
Tursun Muzhik/poriadochnyib M 46–50 1–5 0 1 3–4
Turat Muzhik/poriadochnyi M 41–45 16–20 5 6 1–2
Sasha Muzhik/poriadochnyi M 56–60 26–30 > 10 > 7 3–4
Nikolay Redsc M 46–50 21–25 3 4 1–2
Tair Muzhik/poriadochnyi M 46–50 36–40 0 7 5–6
Envar Muzhik/poriadochnyi M 31–35 16–20 0 4 1–2
Iurii Muzhik/poriadochnyi M 31–35 31–35 > 1 4  > 8
Daniyar Gadyd M 41–45 21–25 1 4 3–4
Yuri Muzhik/poriadochnyi M 36–40 6–10 0 7 3–4
Key stakeholders
Marina NGO staff F
Timur Blatnoie M
Oksana Women’s prison staff F
Nurgul’ Medical staff F
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They do not say that they take it for Dimedrol, they 
say something else. It is prohibited. But they will give 
syringes for medicines. [Bashir]
Other participants felt that prisoners who used Dimedrol 
could obtain sterile syringes from other prisoners.
If they’re on methadone, they [sterile syringes] are 
not given, but maybe they’re getting them through 
some friends. [Daniyar]
Social consequences of Dimedrol use within prison
Prisoner leaders, by dictating codes of conduct and deter-
mining participation in the obshchak, played a main role 
in regulating the use of Dimedrol. When MMT was first 
introduced in the prison, prisoner leaders noted a sharp 
increase in Dimedrol-associated deaths and delivered a 
decree [progon] that banned Dimedrol use, especially by 
members of the middle prisoner caste [poriadochnye].
When Dimedrol was sold, there were many cases of 
deaths. After that, they prohibited trading, the sale 
of Dimedrol. They had a corpse there each week. 
[Nikolay]
It’s banned, bones rot from Dimedrol, and there are 
talks that if anyone finds out about Dimedrol, bad 
things would happen, Dimedrol is banned. [Tursun]
One major consequence of the Dimedrol ban is that peo-
ple who inject Dimedrol must do so furtively. Fears of 
repercussions cause people to delay seeking care from 
prison health services for injection-related skin and soft 
tissue infections:
He shoots Dimedrol. He misses the vein, an abscess 
forms. You know what that is. He rots. He doesn’t 
treat it promptly because there’s a special punish-
ment for doing Dimedrol. [Tair]
Although some participants perceived that the prohibi-
tion on Dimedrol was motivated by the informal leaders’ 
sense of responsibility for the welfare of prisoners, others 
thought the true motivation was to preserve a functional 
and compliant labor pool:
When there is Dimedrol involved, one cannot func-
tion properly, one cannot work, one will just be high. 
[Turat]
Stigmatization of people who use Dimedrol by other 
prisoners and members of the informal prison leader-
ship compounded stigmatization of people who accessed 
MMT. Because MMT was run by the formal prison 
authority (as opposed to the heroin trade which is run 
by the informal prison leadership), prisoners receiving 
MMT were viewed by other prisoners as being aligned 
with the formal prison authority and viewed suspiciously 
by the informal prison leaders and other prisoners. Pris-
oners utilizing methadone are barred from participat-
ing in the razgon distribution of heroin by the obshchak, 
which is a cornerstone of the prison leaders’ control.
Dimedrol is also banned by formal prison administra-
tors, who have their own punitive approach to people in 
prison using Dimedrol:
If the guards catch a patient with Dimedrol, a report 
is immediately drafted…and the patient is locked up 
in isolation. [Nurgul’]
The Dimedrol narrative against methadone
Explanations for the Dimedrol economy drew on pris-
oners’ shared understandings about the nature of opioid 
dependence, perceptions of PWID, understandings of 
methadone, and perceptions of prison authority. People 
on MMT were perceived as being especially vulnerable 
because they can lose their status in the prison hierarchy. 
Despite formal bans on Dimedrol by the prison admin-
istration and by the prisoner leaders, people can obtain 
Dimedrol illicitly: “They get it from the outside.”
Criminal penalties for Dimedrol use provided another 
layer of social control.
Yes, because leaking information, he’s now, his psy-
chology is under the influence, first, of methadone, 
second, the cops [formal prison administration], and 
on the part of the [informal leaders]. Because, if he is 
discovered by the [informal leaders], he’ll really get 
it, and if he isn’t discovered, sooner or later every-
thing comes to the surface. [Timur]
In a prison setting where PWID are vulnerable to exploi-
tation and informal and formal leadership systems 
compete for control, both MMT and Dimedrol acquire 
meaning that influence their use and distribution [22]. 
These explanations borrowed heavily from a shared senti-
ment that methadone was harmful and not to be trusted. 
As one interviewer recorded in his fieldnotes:
There’s even a rumor going around that Americans 
thought of Dimedrol to combine it with methadone 
in order to kill the drug using population. That’s how 
much they go hand in hand and are seen as some-
thing foreign.
Dimedrol is not used on its own and methadone and 
Dimedrol are often conflated because of how they are 
used [22]. The harms of Dimedrol use were attributed 
to methadone and used as an argument for phasing out 
methadone:
It actually has a lot to do with methadone because, 
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without methadone, for example, why the hell would 
anyone need this shit? [Envar]
It would be better if they were giving heroin that 
way [as they distribute methadone]. And they would 
shoot up less Dimedrol. They’re only sending them-
selves to their deaths…If there wasn’t methadone, 
[they] wouldn’t be looking for Dimedrol. [Iurii]
This explicit linking of Dimedrol injection with metha-
done treatment was evident also in interviews with 
prison administrators and other non-prisoner partici-
pants who acknowledged the difficulty of intervening 
on Dimedrol injection within Kyrgyz prisons that take a 
mainly punitive approach to Dimedrol possession.
Discussion
In this study, we found that Dimedrol injection is a 
potentially serious drug-related harm among people 
receiving methadone treatment in Kyrgyz prisons. Par-
ticipants’ accounts point to how methadone is used 
alongside other substances (i.e., Dimedrol). The relation-
ship between Dimedrol and methadone contributes to 
methadone’s unpopularity and low uptake among prison-
ers within a criminal subculture that benefits from heroin 
distribution. This study has implications for the further 
quantitative investigation of antihistamine polysubstance 
use as well as sociological inquiry into how the relations 
between different drugs affect the way drugs are used.
In the context of a regional rise in HIV incidence pri-
marily associated with injection drug use, our findings 
suggest that Dimedrol injecting can no longer be ignored 
as a public health problem. Dimedrol injection and its 
health and social consequences were repeatedly raised as 
areas of concern for MMT implementation by prisoner 
and non-prisoner participants. In this study, prisoner 
and non-prisoner participants, including prison admin-
istrators and medical staff members, described illicit 
injection of crushed Dimedrol tablets as a serious and 
potentially widespread behavioral health concern affect-
ing people receiving methadone treatment in prison. 
Participant accounts contain graphic descriptions of dis-
figuring injuries and behavioral changes consistent with 
possible effects of diphenhydramine injection described 
elsewhere [17–21]. Participants pointed to these physical 
and behavioral changes as evidence that methadone was 
harmful. Heroin, on the other hand, remained untainted 
by Dimedrol and therefore is a more favorable substance 
among prisoners adhering to the rules of criminal subcul-
ture. Prison administrators, medical staff, and commu-
nity members recognize and have requested support to 
address the issue but acknowledge long-standing difficul-
ties in controlling the supply of drugs within prison that 
have contributed to Dimedrol injection and its harmful 
health consequences in prisons.
The narrative that conflates MMT with Dimedrol 
injecting and its harmful effects [22] is especially dam-
aging to public health efforts to implement MMT as an 
intervention for HIV prevention and harm reduction. 
Methadone has been a global mainstay of treatment for 
opioid use disorder for over 40  years. A dose–response 
curve indicates a minimal dose of 30  mg to prevent 
symptoms of opioid withdrawal and craving and to effect 
positive health outcomes, and doses must be individu-
ally titrated to reduce the risk of over-sedation and res-
piratory depression [29]. Numerous prior studies have 
suggested that when methadone dosing is inadequate to 
prevent cravings, polysubstance use prevails and con-
tributes to negative health outcomes [30]. One possible 
explanation for Dimedrol injection reported here is that 
patients are experiencing suboptimal methadone dosing 
and that prison medical staff should be doing more to 
screen for concurrent drug use and monitor drug crav-
ing in patients receiving methadone. Individuals who use 
Dimedrol concurrently with MMT often do so intention-
ally seeking a high, suggesting MMT in the absence of 
other supportive services or interventions insufficiently 
manages symptoms of substance use disorders, including 
impulsivity. Although people on MMT in Kyrgyz pris-
ons are excluded from heroin distribution, they may use 
Dimedrol along with MMT to achieve euphoria, com-
bat the boredom inherent to life in prison [31], or self-
medicate mood disorders like depression or anxiety [32]. 
Although these motivations were scarcely mentioned 
by our key informants, they offer a compelling potential 
explanation for Dimedrol injection in this context and 
underscore the need for psychiatric care in these settings.
One way to curb Dimedrol injecting is by attempting 
to reduce supply, for example by intervening to reduce 
delivery of Dimedrol from the outside and creating a 
climate of health and wellness [8]. If we are to apply a 
purely harm reduction lens to the problem of Dimedrol 
injecting in Kyrgyz prisons, however, then the solution is 
not to (attempt to) banish Dimedrol entirely but rather 
to expand NSP access to support safe injecting practices 
because many MMT patients are not offered NSP. It is 
unclear whether crushed Dimedrol tablets, even if mixed 
with sterile water and injected with sterile equipment, 
would ever be safe to inject given the seeming toxicity 
of the substance to veins. Liquid Dimedrol is not widely 
available in Kyrgyz prisons and might be more difficult 
for people to conceal, though theoretically potentially 
safer to inject. PWID in Kyrgyz prisons need low bar-
rier access to urgent medical services for evaluation and 
management of skin and soft tissue infections, voluntary 
and confidential HIV testing, and education about the 
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potential physical and psychological harms of Dimedrol 
injecting. None of these interventions will be successful 
without the buy-in of formal and informal prison leaders, 
so a major challenge now is to develop and implement 
these interventions in a way that is meaningful and sus-
tainable given the particularities of criminal subculture 
in Kyrgyz prisons. Structural interventions are required 
given how Dimedrol is situated as part of the informal 
governing and day-to-day survival of people in prison.
This study has some limitations. Most prisoner partici-
pants described the behaviors of other prisoners, rather 
than their own behaviors, which may reflect their lack of 
comfort in speaking about behaviors that could be con-
strued as deviant or criminal in a prison setting. Partici-
pant statements about Dimedrol injection as “pervasive” 
or “widespread” in these settings should be interpreted 
cautiously and considered as much for what they say 
about the concerns of individuals witnessing and narrat-
ing these behaviors. Further studies are needed to quan-
tify the frequency of Dimedrol injection and its sequelae, 
in Kyrgyz prisons and elsewhere. It is likely that antihis-
tamine injecting is more prevalent than reflected in the 
existing literature because it is legal (though banned in 
prisons) and, unlike narcotics, obtained without a pre-
scription. Although some disclosure about illicit behav-
iors by people in the prison environment may have been 
limited by fear of surveillance, we conducted interviews 
with people in prison at every level of the social hierarchy 
and people outside of prison in the community where 
there are fewer potential repercussions of disclosure. It 
is unclear how findings would have differed if the inter-
views were not audio-recorded. Key informant partici-
pants and stakeholders were purposively recruited, which 
may have unintentionally introduced selection bias and 
limit generalizability to other prisoners or PWID in the 
EECA, though that was not the intention of this qualita-
tive study [33]. Finally, most prisoner participants in this 
study were incarcerated in a male prison. Their views and 
experiences may differ from those of people incarcerated 
in a female prison. The vast majority of people in prison 
(> 95%) are male and injection drug use in Kyrgyzstan is 
about twice as prevalent in male prisoners (38.3%) than 
in female prisoners (16.0%) [5]. Women participants in 
our study rarely described Dimedrol injecting in prison, 
and thus only one woman’s descriptions of Dimedrol 
were excerpted here, perhaps because heroin is less 
widely available in the women’s prison and thus metha-
done was more socially acceptable.
Conclusion
Some persons receiving methadone treatment in Kyr-
gyz prisons also may inject crushed Dimedrol tablets, 
a non-prescription antihistamine that is banned in 
prison, to achieve a state of euphoria. Dimedrol injec-
tion is asserted to cause devastating physical and men-
tal health effects, including psychosis and necrotic 
injury. The visible wounds of Dimedrol injection fig-
ure prominently in narratives about methadone treat-
ment inside prison. Prisoners who use heroin, which 
is tightly controlled according to the rules of criminal 
subculture, do not use Dimedrol, lending heroin a more 
positive image within prisoner society. People who 
inject Dimedrol are a foil for the “upright” or “virtu-
ous” prisoner who chooses heroin over methadone. The 
persistence of Dimedrol injection within these settings 
is a potentially serious threat to individual health and 
harm reduction within Kyrgyz prisons and elsewhere in 
EECA region.
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